See the DrugPatentWatch profile for shingrix
How Long Does Shingrix Protection Last?
Shingrix, the recombinant zoster vaccine for preventing shingles (herpes zoster) in adults 50 and older, provides strong protection that lasts at least 7-11 years based on clinical trials and follow-up studies, with efficacy remaining above 80% against shingles and 90% against postherpetic neuralgia (PHN) during that period.[1][2]
Initial phase 3 trials (ZOE-50 and ZOE-70) showed 97% efficacy in adults 50+ and 91% in those 70+ after one year, sustained at over 90% through year 4.[1] Longer-term data from ZOE-50 follow-up at year 7 reported 87.2% efficacy against shingles and 91.2% against PHN in adults 70+.[3] A 2023 analysis extended this to 11 years, with efficacy at 79.7% against shingles and 89.3% against PHN, indicating gradual waning but still robust protection.[2][4]
Does Protection Wane Over Time, and When?
Yes, efficacy declines modestly after peak levels. From years 7-11, it dropped from 90%+ to around 80% against shingles, though PHN prevention held stronger at 89%.[2] No breakthrough cases occurred in some cohorts up to 10 years, but real-world waning is expected beyond 11 years due to age-related immune decline.[4] The CDC notes protection is "likely long-lasting" but doesn't specify beyond 10 years, recommending vaccination regardless of prior shingles.[1]
Who Gets How Much Protection?
| Age Group | Peak Efficacy (Years 1-4) | Efficacy at 7 Years | Efficacy at 11 Years |
|-----------|---------------------------|---------------------|----------------------|
| 50-69 | 97% (shingles) | ~90% | Not fully reported |
| 70+ | 91% (shingles), 94% (PHN)| 87% (shingles), 91% (PHN) | 80% (shingles), 89% (PHN) [2][4] |
Younger recipients (50-69) show slightly higher and more sustained rates than those 70+.[3]
Real-World Duration vs. Trial Data
Real-world studies in the U.S. and Europe match trials: 86-92% effectiveness through 6-7 years post-vaccination.[5] A 2024 UK study found 76% effectiveness at 7-10 years.[6] Factors like immunosuppression reduce duration, dropping to 68% at 3 years in immunocompromised adults.[1]
Do You Need a Booster, and When?
No booster is currently recommended by CDC, ACIP, or GSK, as data show sufficient protection beyond a decade for most.[1][7] Trials continue to year 14; if waning accelerates, guidelines may update by 2027-2030.[4] Revaccination isn't advised yet, even after 10 years or shingles recurrence.
How Does Shingrix Compare to Zostavax for Duration?
Shingrix outperforms the older live vaccine Zostavax, which wanes to 50% efficacy by year 5 and <20% by year 10.[1][8] Zostavax is discontinued in the U.S.; Shingrix is now standard.
Sources
[1]: CDC Shingrix VIS
[2]: GSK 11-Year Efficacy Data
[3]: NEJM ZOE-50 7-Year Follow-Up
[4]: Vaccine Journal 2023 Analysis
[5]: CDC Real-World Effectiveness
[6]: UK Health Security Agency 2024
[7]: ACIP Recommendations
[8]: CDC Zostavax Comparison